Tazarotene versus tazarotene plus clindamycin/benzoyl peroxide in the treatment of acne vulgaris: a multicenter, double-blind, randomized parallel-group trial.
Topical retinoids offer highly effective treatment for both inflammatory and non-inflammatory acne, with tazarotene demonstrating greater efficacy than other topical retinoids. A multicenter, double-blind, randomized, parallel-group trial has been performed to evaluate whether the adjunctive use of clindamycin/benzoyl peroxide could enhance the efficacy of tazarotene still further. Patients with moderate to severe inflammatory acne applied tazarotene 0.1% cream each evening and were randomly assigned to morning applications of vehicle gel or a ready-to-dispense formulation of clindamycin 1%/benzoyl peroxide 5 % gel containing 2 emollients. Tazarotene/clindamycin/benzoyl peroxide achieved a significantly greater reduction in comedo count than tazarotene monotherapy and, among patients with a baseline papule plus pustule count of > or =25 (the median value), a significantly greater reduction in inflammatory lesion count. The combination therapy was also at least as well-tolerated as tazarotene monotherapy. The adjunctive use of clindamycin/benzoyl peroxide gel with tazarotene cream promotes greater efficacy and may also enhance tolerability. Any improvements in tolerability could be due to the emollients in the clindamycin/benzoyl peroxide gel formulation.
Tanghetti
Emil
E
Department of Dermatology, University of California at Davis, Sacramento, USA. et@mgci.com
Abramovits
William
W
Solomon
Barry
B
Loven
Keith
K
Shalita
Alan
A
D000152:Acne Vulgaris / Q000188:drug therapy* / Q000473:pathology; D000279:Administration, Cutaneous; D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D001585:Benzoyl Peroxide / Q000008:administration & dosage; D002981:Clindamycin / Q000008:administration & dosage*; D003879:Dermatologic Agents / Q000008:administration & dosage*; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D004643:Emollients / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008297:Male; D009539:Nicotinic Acids / Q000008:administration & dosage*; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014481:United States; D012176:Retinoids
D000900:Anti-Bacterial Agents; D001585:Benzoyl Peroxide; D002981:Clindamycin; D003879:Dermatologic Agents; D004643:Emollients; D009539:Nicotinic Acids; C086827:tazarotene; D012176:Retinoids